Showing 5321-5330 of 8887 results for "".
- Ted Danson Partners with Bristol Myers Squibb for Plaque Psoriasis Campaignhttps://practicaldermatology.com/news/ted-danson-partners-with-bristol-myers-squibb-for-plaque-psoriasis-campaign/2462442/Bristol Myers Squibb has partnered with award-winning actor Ted Danson, who lives with plaque psoriasis, for a new campaign called “
- Study Highlights Orofacial Anomalies in Kindler Epidermolysis Bullosahttps://practicaldermatology.com/news/orofacial-anomalies-in-kindler-epidermolysis-bullosa/2462441/A new study in JAMA Dermatology suggests that hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa (KEB). "Kindler epidermolysis bullosa is a genetic skin-blistering disease associated with recessive inherited pathogenic varia
- Mediterranean Diet Adherence Not a Factor in Diagnosis or Severity of Acne: Studyhttps://practicaldermatology.com/news/mediterranian-diet-not-linked-with-acne-development-study/2462437/Results from a new analysis in the Journal of Health, Population, and Nutrition failed to show a link between adherence to a Mediterranean diet and an impact on acne severity or diagnosis. "Western diets, characterized by a high glycemic index and dairy content, can be risk fact
- Almirall Partners with Eloxx Pharmaceuticals to Target Rare Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-partners-with-eloxx-pharmaceuticals-to-target-rare-dermatological-diseases/2462435/Almirall and Eloxx Pharmaceuticals, Inc., announced today that they have partnered to exclusively license ZKN-013, in what they call a "potential game-changer" for the treatment of rare dermatological disorders. The agreement grants Almirall global rights to develop
- Analysis of Dermatology Mobile Apps with AI Capability Reveals Weaknesses, Transparency Concernshttps://practicaldermatology.com/news/analysis-of-dermatology-mobile-apps-reveals-weaknesses-transparency-concerns/2462434/A new analysis of dermatology mobile applications (apps) revealed transparency, validation, and accuracy concerns. "With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applicat
- INTEGUMENT-PED: Roflumilast Cream 0.05% Effective at Improving AD in Childrenhttps://practicaldermatology.com/news/integument-ped-roflumilast-cream-005-effective-at-improving-ad-in-children/2462429/New data from a pivotal phase 3 trial indicates roflumilast cream 0.05% is associated with significantly improved atopic dermatitis (AD) in children 2 to 5 years of age with mild-to-moderate AD. Researchers for the Interventional Trial Evaluating Roflumilast Cream for the Treatment of Ato
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experienci
- Analysis: Alopecia Areata Linked with Work Productivity Losseshttps://practicaldermatology.com/news/analysis-alopecia-areata-linked-with-work-productivity-losses/2462430/Results from a new real-world analysis illuminated demographic and clinical characteristics associated with productivity losses in individuals with alopecia areata. “Patients with alopecia areata experience poor health-related quality of life and significant disease burden,” the authors w
- Study: Seborrheic Dermatitis Has Distinct Molecular Signaturehttps://practicaldermatology.com/news/study-seborrheic-dermatitis-has-distinct-molecular-signature/2462428/Newly unveiled research suggests that seborrheic dermatitis has its own unique molecular signature and is distinct in its own disease-specific pattern. “The pathophysiology of seborrheic dermatitis has been poorly understood. We sought to understand the gene expression patterns in seborrh
- Ruxolitinib Cream 1.5% Effective in Hidradenitis Suppurativa Hurley Stage 1 or 2 Patientshttps://practicaldermatology.com/news/ruxolitinib-cream-15-shows-efficacy-for-hidradenitis-suppurativa-hurley-stage-1-or-2-patients/2462427/Data from a new phase 2 trial indicate twice-daily ruxolitinib cream, 1.5% (OpzeluraTM, Incyte) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS) was safe and effective. The primary endpoint of the study was achieved, with patients on t